"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Because most of the major risk factors are beyond your control, there’s no proven way to truly reduce ...

Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

Researchers found men who ejaculated more often had fewer prostate cancer diagnoses, pointing to a possible biological ...

September is Prostate Health Awareness Month, providing an opportune time for men to consider their prostate health and take steps to help reduce the likelihood of developing prostate cancer. Prostate ...

Risk factors are things that raise your chances of getting a disease. For each person, there’s a mix of genetic, biological and lifestyle factors that play a part in prostate cancer risk. About 1 in ...

Having prostate cancer can be terrifying but there are ways to reduce the risk of getting it.  The risk of developing prostate cancer progressively increases with age and many men haven't found a ...

This article was reviewed by Darragh O’Carroll, MD. PSA and Testosterone: Are They Linked? Prostate-specific antigen (PSA) is a term you’ll probably become familiar with once you start getting ...

Former US President Joe Biden has been diagnosed with prostate cancer, according to a statement from his office on Sunday. Mr Biden sought medical attention last week due to urinary symptoms, and a ...

Men living in US counties with a higher prevalence of PSA screening are less likely to have advanced prostate cancer and to die from it. In the United States, access to county-based PSA screening is ...

Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on disease progression. Among patients with intermediate-risk prostate cancer, ...

It’s important to follow guidance on prostate-specific antigen screening that maximizes benefits and minimizes potential harms such as overdiagnosis and overtreatment.

An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...